BE Biosol and the Bill & Melinda Gates Foundation announce a partnership to expand global access to ferric carboxymaltose, an injectable treatment used to address anaemia. The deal focuses on increasing availability and reach of the therapy in relevant markets.

Both outlets describe the arrangement in similar terms, framing it as an effort to tackle anaemia through broader distribution of the medication. The reporting does not specify countries, timelines, or dosing details in the provided excerpts, so the emphasis remains on the collaboration and its intended public-health goal.

The Hindu presents the announcement as an “ink pact” for anaemia-related injection use, while Times of India leads with the partnership’s expansion theme and directly ties it to improving access worldwide to ferric carboxymaltose.